Press Releases - 2022-09-10

Date	Title	Company
10-Sep-2022	Bicara Therapeutics Presents New Data from Ongoing Phase 1/1b Trial of Lead First-in-Class Bifunctional Program, BCA101, at the European Society for Medical Oncology (ESMO) Congress 2022	Businesswire
10-Sep-2022	Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022	Businesswire
10-Sep-2022	Wugen Presents Preclinical Data on WU-NK-101 in Solid Tumor Models at the European Society for Medical Oncology (ESMO) Congress 2022	Businesswire
10-Sep-2022	Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022	Businesswire
10-Sep-2022	Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis	Businesswire
10-Sep-2022	BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer	Businesswire
10-Sep-2022	U.S. Food and Drug Administration Approves Sotyktu™ (deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis	Businesswire